SCHEMBL5215670

SCHEMBL5215670

O=C1CCC(N2C=Nc3ccc(Cl)cc3C2)C(=O)N1

nearest known ligand 0.44

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 18/20 0.44
DDB1 Q16531 9/20 0.44
PDE3B Q13370 1/20 0.43
PDE3A Q14432 1/20 0.43
IKZF3 Q9UKT9 4/20 0.40
ALDH1A1 P00352 1/20 0.39
CHRM2 P08172 1/20 0.39
OPRM1 P35372 1/20 0.39
CYP1A2 P05177 1/20 0.39
TSHR P16473 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5215782 0.91 CRBN (0.44) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL1398031 0.88 PDE3B (0.45) CRBNDDB1PDE3BPDE3AALDH1A1
SCHEMBL5213729 0.86 CRBN (0.50) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL5218003 0.83 PDE3B (0.46) CRBNDDB1PDE3BPDE3AIKZF3
SCHEMBL5162159 0.83 CRBN (0.58) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL5215745 0.81 CRBN (0.50) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL5217927 0.81 CRBN (0.43) CRBNDDB1IKZF3
SCHEMBL5217370 0.79 CRBN (0.56) CRBNDDB1IKZF3
SCHEMBL5216879 0.79 CRBN (0.50) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL1398102 0.78 KMT2A (0.40) CRBNDDB1PDE3BPDE3AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1456197-B1 PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 GRUENENTHAL GMBH (DE) 2007-02-28 EP claimed
US-7183274-B2 Piperidine-2,6-diones heterocyclically substituted in the 3-position GRUENENTHAL GMBH (DE) 2007-02-27 US claimed
US-20050020581-A1 Piperidine-2,6-diones heterocyclically substituted in the 3-position GRUENENTHAL GMBH (DE) 2005-01-27 US claimed
EP-1456197-B1 PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 GRUENENTHAL GMBH (DE) 2007-02-28 EP disclosed
US-7183274-B2 Piperidine-2,6-diones heterocyclically substituted in the 3-position GRUENENTHAL GMBH (DE) 2007-02-27 US disclosed
US-20050020581-A1 Piperidine-2,6-diones heterocyclically substituted in the 3-position GRUENENTHAL GMBH (DE) 2005-01-27 US disclosed
EP-1456197-A1 PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 Grünenthal GmbH (DE) 2004-09-15 EP disclosed
WO-2003053956-A1 PIPERIDINE-2,6-DIONES THAT ARE HETEROCYCLICALLY SUBSTITUTED IN POSITION 3 Grünenthal GmbH (DE) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020581-A1 Piperidine-2,6-diones heterocyclically substituted in the 3-position DPYD, CYP2D6, DHPS CRBN 4553/4885DDB1 4687/4885PDE3B 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.